D59.13
Mixed type autoimmune hemolytic anemia
Clinical Classification Guidelines
Inclusion Terms
- Mixed type autoimmune hemolytic disease
- Mixed type, cold and warm, (primary) (secondary) (symptomatic) autoimmune hemolytic anemia
Medical Intelligence & Overview
Mixed autoimmune hemolytic anemia (AIHA) is a rare blood disorder where the immune system mistakenly attacks and destroys red blood cells. This condition involves a combination of both warm and cold antibody types, making it complex to diagnose and treat. AIHA can be primary, occurring without an apparent cause, or secondary, linked to other health conditions. Recognizing the signs and understanding the underlying causes are essential steps toward effective management.
Causes & Symptoms
Clinical Causes: Autoimmune reactions where the body's immune system produces antibodies against its own red blood cells. Secondary autoimmune hemolytic anemia caused by underlying conditions such as lymphomas, leukemias, certain infections, or autoimmune diseases like lupus. Use of certain medications that may trigger immune responses against red blood cells. Idiopathic cases, where no specific cause can be identified.
Key Symptoms: Fatigue and weakness due to anemia Shortness of breath, especially during physical activity Pale or jaundiced skin (yellowish tint) Rapid heartbeat Dark-colored urine Sensations of cold or warmth in the fingers and toes Splenomegaly (enlarged spleen)
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a combination of blood tests to identify anemia and immune activity against red blood cells. These may include:
Treatment Protocols: Managing mixed autoimmune hemolytic anemia aims to suppress the immune response and address symptoms. Common treatments include:
Clinical Advice & FAQs
Billing Guidance
Is D59.13 a billable ICD-10 code?
Yes, D59.13 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D59.13?
Clinical documentation must specify the nature of Mixed type autoimmune hemolytic anemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference